Aveo ISIN: US0535883070 Forum: Aktien User: Gambler10101

Es ist Zeit sich zu verabschieden, der Deal ist seit gestern endgültig durch, zu 15 Dollar je Aktie. Viel Glück allen an der Börse.

Wie wird die Übernahme abgewickelt, werden die Aktien zu 15€ abgekauft und das Geld auf dem Konto gutgeschrieben oder bleibt die Aktie oder erhält man LG Chem Aktien in Bezug auf seine Anteile?

15 Dollar ist Schluss, es sei denn es gibt einen weiteren Käufer der mehr zahlt.

Abend zusammen, hab eine Aveo‘s seit Jahren aber komplettes Depot und Börsennews bewusst gemeidet… alles ging den Bach runter. Nun steht die Aveo bei grob 15€ Bin nicht mehr informiert. Gambler, was meinst. Wo geht die Reise hin.

Ist lächerlich der Preis. Jetzt wo die Firma kurz davor steht profitabel zu sein und eine Patentverlängerung bis 2039 hat... ist ein Witz und eine Verarschung der Anleger.

Passt 🥂🍀

Aveo 15 Dollar buyout by LG Chem.

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma https://www.globenewswire.com/news-release/2022/10/12/2533371/0/en/U-S-Patent-Trademark-Office-Allows-AVEO-Oncology-s-Patent-Application-Covering-Use-of-FOTIVDA-for-the-Treatment-of-Refractory-Advanced-Renal-Cell-Carcinoma.html

Wenn Herabstufungen so enden, ist es ok 😉

https://realmoney.thestreet.com/investing/stocks/the-trade-on-this-small-oncology-concern-16080492

AVEO Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $25.3M misses by $0.17M https://seekingalpha.com/news/3867642-aveo-pharmaceuticals-gaap-eps-of--024-beats-by-004-revenue-of-253m-misses-by-017m?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain • AVEO Pharmaceuticals press release (NASDAQ:AVEO): Q2 GAAP EPS of -$0.24 beats by $0.04. • Revenue of $25.3M (+232.9% Y/Y) misses by $0.17M. • AVEO believes that its $77.2M in cash, cash equivalents and marketable securities as of June 30, 2022, along with expected net product revenues from the sales of FOTIVDA in the United States, will enable AVEO to maintain its current operations for a period of more than 12 months from the date of filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. • AVEO has reaffirmed its full year 2022 FOTIVDA U.S. net product revenue guidance of $100.0 million to $110.0 million. AVEO expects that commercial expenses will be approximately $50.0 million in 2022. AVEO expects general and administrative expenses will remain at approximately $20.0 million for the year. Research and development expenses are now expected to be approximately $50.0 million in 2022, a reduction from the prior range of $60.0 million to $70.0 million. • In addition, AVEO expects that gross margins will continue to be in the mid-to-high 80th percentile in 2022.

AVEO Oncology Reports Second Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/08/04/2492814/0/en/AVEO-Oncology-Reports-Second-Quarter-2022-Financial-Results.html – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – ...

AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC https://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-clinical-trial-collaboration-and-0 - This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 - ...

"AVEO Oncology Announces Updated NCCN Clinical Practice" https://www.globenewswire.com/news-release/2022/06/21/2466109/0/en/AVEO-Oncology-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Elevate-FOTIVDA-tivozanib-to-Category-1-Treatment-for-Relapsed-or-Refractory-Advanced-R-R-Renal-Cell-Carcinoma-RCC.html

AVEO Oncology Reports First Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/05/05/2436618/0/en/AVEO-Oncology-Reports-First-Quarter-2022-Financial-Results.html – Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – ...